Aiosyn

Aiosyn is a Netherlands-based company that specializes in computational pathology using advanced artificial intelligence (AI) and deep learning technologies. Founded as a spin-off from the Computational Pathology research group at Radboud University Medical Center, Aiosyn draws on over 20 years of pathology research experience. The company focuses on developing software solutions that integrate AI into pathology workflows, particularly for cancer and kidney disease diagnosis and research. Aiosyn aims to enhance precision pathology by embedding deep learning algorithms into clinical workflows. Their AI-powered software provides pathologists and biopharma companies with data-driven insights that improve diagnostic accuracy and optimize workflow efficiency. The team consists of scientists, engineers, regulatory experts, medical professionals, and business specialists dedicated to creating practical tools for healthcare providers. Aiosyn collaborates closely with clinical pathologists to ensure their solutions meet the needs of real-world pathology practice, with a vision to make AI-powered tools widely accessible for better patient care.

• Employees 7
• Founded 2021
• Total Funding $2123300